Lawsuit accuses diabetic drug manufacturer Takeda of not warning of risks of bladder cancer
A diabetic has filed a lawsuit against the manufacturer of his prescription glucose medication for not warning that the drug carries an increased risk of bladder cancer after more than 12 months of the drug's use.
Tommy G. Thompson and Lua Thompson filed suit against Takeda Pharmaceuticals North America Inc., Takeda Global Research & Development Center Inc., Takeda Pharmaceuticals Company Ltd., Takeda Pharmaceuticals America Inc., Takeda San Diego Inc., Takeda Pharmaceuticals International Inc. and Eli Lilly and Co. on Sept. 9 in federal court in New Orleans.
Tommy Thompson claims he was injured due to taking the drug Actos, a prescription medication used to improve blood sugar (glucose) control in adults with type II diabetes. Specifically, he argues that the defendants concealed the risk of bladder cancer associated with more than twelve months of Actos ingestion.
The plaintiffs are seeking an award of actual damages for pain and suffering, ascertainable economic losses, costs of obtaining Actos, medical expenses, loss of
consortium, interest, costs, expenses and attorney's fees.
Thompson is represented by Richard J. Arsenault and C. Michael Bollinger and Neblett, Beard & Arsenault in Alexandria. A jury trial is requested.
U.S. District Judge Helen G. Berrigan is assigned to the case.
Case No. 2:11-cv-02279